Latest From Generation Bio
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.
Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- North America
- Company Type
- Parent & Subsidiaries
- Generation Bio
- Senior Management
Geoff McDonough, MD, President & CEO
Glenn Goodard, CFO
Mark Angelino, PhD, Founder & COO
Doug Kerr, MD, PhD, Head of R&D
Rob Kotin, PhD, Founder & Head of Discovery
Geary Macquiddy, Senior Director, Program Management
Phillip Samayoa, PhD, Senior Director, Strategy & Portfolio Dev
Matt Stanton, PhD, Head, Platform Research
Jennifer Elliott, PhD, JD, VP, Head of Legal and IP
Will McCarthy, CBO
- Contact Info
215 First Street
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.